BIOMAT Database Logo BIOMAT Database Logo

Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells. 2017

Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
a Urologic Clinical Center of Gansu Province, Key Laboratory of Gansu Province, Institute of Urology, The Second Hospital of Lanzhou University , Lanzhou , China.

Gene therapy combined with radiation has shown promising potential for the treatment of tumors. This paper aimed to clarify the synergistic effect of radiotherapy combined with the bladder cancer tissue-specific oncolytic adenovirus (Ad-PSCAE-UPII-E1A) on bladder cancer cells and to study the underlying synergy mechanisms of the combined treatment. The Adenovirus carrying E1A under control of UPII promoter and prostate stem cell antigen enhancer (PSCAE) were successfully constructed. The viability of bladder cancer cells BIU-87 and EJ was determined by MTT assay. The apoptotic assay was demonstrated by flow cytometry and TEM. Virus titer was determined by TCID50 assay, and proteins Mre11, Chk2-Thr68, and E1A were analyzed by Western blot method. Oncolytic adenovirus combined with radiotherapy improved antitumor efficacy compared with the single treatment at a time and was X-ray dosage-dependent. When the adenovirus infection was scheduled at 24 h after irradiation, cancer cells had the lowest viability. Adenovirus and irradiation induced cell death through the caspase-3 related apoptotic pathway, and bladder cancer cells were arrested at the G1 (BIU-87) or S phase (EJ). Autophagic vacuoles were observed in bladder cancer cells treated with radiation and adenovirus. After irradiation, more virus particles were observed in the BIU-87 and EJ cells. However, by a TCID50 assay, there was no difference in virus titter between irradiated bladder cancer cells and unirradiated cells. The proteins Mre11, Chk2-Thr68 which involved in the DNA break repair pathway were decreased while γ-H2AX-Ser139 increased; at the same time, the E1A gene and the hexon proteins of oncolytic adenovirus were increased after irradiation. Our results proved synergistic antitumor effect of adenovirus Ad-PSCAE-UPII-E1A and radiation, which might be a potential therapeutic strategy for bladder cancer.

UI MeSH Term Description Entries
D011995 Recombination, Genetic Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses. Genetic Recombination,Recombination,Genetic Recombinations,Recombinations,Recombinations, Genetic
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000256 Adenoviridae A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases. Adenoviruses,Ichtadenovirus,Adenovirus,Ichtadenoviruses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D050130 Oncolytic Virotherapy Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells. Oncolytic Virus Therapy,Virotherapy, Oncolytic,Oncolytic Virotherapies,Oncolytic Virus Therapies,Therapies, Oncolytic Virus,Therapy, Oncolytic Virus,Virotherapies, Oncolytic,Virus Therapies, Oncolytic,Virus Therapy, Oncolytic
D050504 Oncolytic Viruses Tumor-selective, replication competent VIRUSES that have antineoplastic effects. This is achieved by producing cytotoxicity-enhancing proteins and/or eliciting an antitumor immune response. They are genetically engineered so that they can replicate in CANCER cells but not in normal cells, and are used in ONCOLYTIC VIROTHERAPY. Oncolytic Virus,Virus, Oncolytic,Viruses, Oncolytic

Related Publications

Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.
August 2017, Virology journal,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice.
January 2021, Current gene therapy,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Antitumor effect of a dual cancer-specific oncolytic adenovirus on prostate cancer PC-3 cells.
June 2019, Urologic oncology,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Stability analysis on the radioactive iodine-labelled prostate cancer-specific recombinant oncolytic adenovirus.
December 2017, Oncology letters,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells.
May 2015, Cell death & disease,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.
October 2012, The British journal of ophthalmology,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells.
November 2020, Experimental cell research,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Synergistic antitumor effect of the combination of a dual cancer-specific oncolytic adenovirus and cisplatin on lung cancer cells.
November 2018, Oncology letters,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells.
March 2014, Head & neck,
Hongjuan Zhang, and Fang Wang, and Chunjie Mao, and Zuncheng Zhang, and Shengjun Fu, and Jianzhong Lu, and Zhenxing Zhai, and Renju Li, and Shuwen Li, and Ron Rodriguez, and Zhiping Wang
Anti-tumour effects of a dual cancer-specific oncolytic adenovirus on Breast Cancer Stem cells.
January 2021, Journal of cellular and molecular medicine,
Copied contents to your clipboard!